Q1 25 EPS
$2.34
BEAT +12.78%
Est. $2.07
Q1 25 Revenue
$984.2M
BEAT +4.48%
Est. $941.9M
vs S&P Since Q1 25
+39.1%
BEATING MARKET
CRL +72.0% vs S&P +32.9%
Market Reaction
Did CRL Beat Earnings? Q1 2025 Results
Charles River Laboratories delivered a stronger-than-expected first quarter, posting non-GAAP EPS of $2.34 and beating the $2.07 consensus estimate by 12.78%, even as revenue declined 2.7% year-over-year to $984.17 million, itself clearing the $941.9… Read more Charles River Laboratories delivered a stronger-than-expected first quarter, posting non-GAAP EPS of $2.34 and beating the $2.07 consensus estimate by 12.78%, even as revenue declined 2.7% year-over-year to $984.17 million, itself clearing the $941.94 million estimate by 4.48%. The earnings outperformance was driven largely by favorable below-the-line factors, including a lower tax rate, reduced interest expense, and fewer diluted shares outstanding, the last of which reflects an aggressive $350.00 million buyback that retired 2.1 million shares in the quarter alone. The single most consequential development, however, was a sharp rebound in Discovery and Safety Assessment bookings, which reached their highest level in two years, offering early evidence that the prolonged biotech spending downturn may be easing. Management translated that momentum into a raised 2025 outlook, now guiding for non-GAAP EPS of $9.30 to $9.80 and a narrower revenue decline of 5.5% to 3.5%, though CEO James Foster struck a cautious tone given ongoing macro and regulatory uncertainties, including escalating legal costs tied to government investigations into the company's non-human primate supply chain.
Key Takeaways
- • DSA booking activity reached the highest level in two years, indicating demand stabilization
- • Cost savings from restructuring initiatives drove non-GAAP operating margin expansion to 19.1% from 18.5%
- • Favorable below-the-line items including lower tax rate, reduced interest expense, and fewer diluted shares outstanding increased non-GAAP EPS
- • Lower NHP shipments in China and lower Cell Solutions revenue pressured RMS segment
- • Discovery services revenue decline drove organic DSA revenue down 1.4%
- • CDMO and Biologics Testing businesses pressured Manufacturing segment organic revenue
- • Higher small research model sales driven by higher pricing partially offset RMS declines
- • Reduction in depreciation expense of $3.4 million ($0.07 per share) from change in useful life estimates for property, plant and equipment
CRL YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
CRL Revenue by Segment
With YoY comparisons, source: SEC Filings
“The first quarter demonstrated continued signs of demand stabilization, highlighted by a notable improvement in DSA booking activity to the highest level in two years. This positive development was tempered by the general undertone of uncertainty in the broader market environment, which has led us to a balanced yet cautious view of the remainder of the year. Taking these factors into account, we are modestly increasing our financial guidance for 2025.”
— James C. Foster, Q1 2025 Earnings Press Release
CRL Earnings Trends
CRL vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CRL EPS Trend
Earnings per share: estimate vs actual
CRL Revenue Trend
Quarterly revenue: estimate vs actual
CRL Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.94 | $2.06 | +5.99% | $995.8M | +1.88% |
| Q4 25 BEAT FY | $2.35 | $2.39 | +1.91% | $994.2M | +0.73% |
| FY Full Year | $10.24 | $10.28 | +0.43% | $4.02B | +0.23% |
| Q3 25 BEAT | $2.34 | $2.43 | +3.86% | $1.00B | +1.42% |
| Q2 25 BEAT | $2.50 | $3.12 | +24.59% | $1.03B | +4.78% |
| Q1 25 BEAT | $2.07 | $2.34 | +12.78% | $984.2M | +4.48% |